Aurobindo Pharma submits supplemental application for Mycophenolate Mofetil
Aurobindo Pharma has submitted a supplemental application for Mycophenolate Mofetil under ANDA217937.
Published: August 2, 2026
Updated: August 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / Immunosuppressant
Company: Aurobindo Pharma
Asset: Aurobindo
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Aurobindo Pharma
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Aurobindo Pharma's supplemental application for Mycophenolate Mofetil could significantly impact the competitive landscape in the immunosuppressant market. Portfolio teams need to evaluate potential shifts in market share and pricing strategies as a result of this submission.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approval announcements.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.